PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28145471-0	2017	Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.	Metformin	23-32	glucagon-like peptide 1 receptor	Mus musculus	90-104	
28145471-6	2017	Metformin upregulated GLP-1 receptor (GLP-1R) level and protein kinase A (PKA) phosphorylation.	Metformin	0-9	glucagon-like peptide 1 receptor	Mus musculus	22-36	
28145471-6	2017	Metformin upregulated GLP-1 receptor (GLP-1R) level and protein kinase A (PKA) phosphorylation.	Metformin	0-9	glucagon-like peptide 1 receptor	Mus musculus	38-44	
28145471-8	2017	Furthermore, AMPK inhibitor compound C abolished the metformin-mediated upregulation of GLP-1R level and PKA phosphorylation.	Metformin	53-62	glucagon-like peptide 1 receptor	Mus musculus	88-94	
28145471-10	2017	Moreover, metformin stimulates GLP-1R and PKA signalling via AMPK-dependent pathway, which may account for its synergistic protective effects with liraglutide.	Metformin	10-19	glucagon-like peptide 1 receptor	Mus musculus	31-37	
20972533-4	2011	METHODS: Metformin action was assessed in Glp1r(-/-), Gipr(-/-), Glp1r:Gipr(-/-), Pparalpha (also known as Ppara)(-/-) and hyperglycaemic obese wild-type mice with or without the GLP-1 receptor (GLP1R) antagonist exendin(9-39).	Metformin	9-18	glucagon-like peptide 1 receptor	Mus musculus	42-47	
26302449-0	2015	Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R).	Metformin	0-9	glucagon-like peptide 1 receptor	Mus musculus	95-127	
26302449-0	2015	Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R).	Metformin	0-9	glucagon-like peptide 1 receptor	Mus musculus	129-135	
26302449-5	2015	Interestingly, metformin, one of the biguanide drugs that has anti-diabetic effects, attenuated lipotoxicity-induced mesangial cell apoptosis and restored GLP-1R expression.	Metformin	15-24	glucagon-like peptide 1 receptor	Mus musculus	155-161	
26302449-12	2015	Furthermore, we provided the evidence that metformin treatment has a renal protective effect partly via increased mesangial GLP-1R expression.	Metformin	43-52	glucagon-like peptide 1 receptor	Mus musculus	124-130	
26302449-13	2015	Our data suggested that regulation of GLP-1R expression could be a promising approach to treat diabetic nephropathy and the novel mechanism of metformin mediated GLP-1R regulation.	Metformin	143-152	glucagon-like peptide 1 receptor	Mus musculus	38-44	
26302449-13	2015	Our data suggested that regulation of GLP-1R expression could be a promising approach to treat diabetic nephropathy and the novel mechanism of metformin mediated GLP-1R regulation.	Metformin	143-152	glucagon-like peptide 1 receptor	Mus musculus	162-168	
20972533-4	2011	METHODS: Metformin action was assessed in Glp1r(-/-), Gipr(-/-), Glp1r:Gipr(-/-), Pparalpha (also known as Ppara)(-/-) and hyperglycaemic obese wild-type mice with or without the GLP-1 receptor (GLP1R) antagonist exendin(9-39).	Metformin	9-18	glucagon-like peptide 1 receptor	Mus musculus	65-70	
20972533-8	2011	Metformin significantly improved oral glucose tolerance despite loss of incretin action in Glp1r(-/-), Gipr(-/-) and Glp1r(-/-) :Gipr(-/-) mice, and in wild-type mice fed a high-fat diet and treated with exendin(9-39).	Metformin	0-9	glucagon-like peptide 1 receptor	Mus musculus	117-122	
20972533-9	2011	Levels of mRNA transcripts for Glp1r, Gipr and Pparalpha were significantly increased in islets from metformin-treated mice.	Metformin	101-110	glucagon-like peptide 1 receptor	Mus musculus	31-36	
20972533-12	2011	CONCLUSIONS/INTERPRETATION: As metformin modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-alpha, metformin may be mechanistically well suited for combination with incretin-based therapies.	Metformin	31-40	glucagon-like peptide 1 receptor	Mus musculus	124-129	
20972533-12	2011	CONCLUSIONS/INTERPRETATION: As metformin modulates multiple components of the incretin axis, and enhances expression of the Glp1r and related insulinotropic islet receptors through a mechanism requiring PPAR-alpha, metformin may be mechanistically well suited for combination with incretin-based therapies.	Metformin	215-224	glucagon-like peptide 1 receptor	Mus musculus	124-129